LuminOne Journal
Writing for sales, BD, and commercial operations leaders who are trying to turn market movement into sourced, approved action without adding another dashboard.
Featured
The USPTO rescinded its 2024 AI inventorship guidance in November 2025 and replaced it with a simpler rule: AI is a tool, and the ordinary conception test applies. Here is what that means for CDMOs, CROs and tools manufacturers.
blog
Anthropic's watermark changes how the model picks between equally good words. It adds no hidden characters, carries no identifying information, and barely forms on the short factual writing most technical sellers produce.
blog
Selling instruments, consumables and reagents into life sciences is not high-volume B2B sales. The account universe is finite, the buyer is a scientist, and the trigger is the customer's program moving, not your quarter.
blog
A practical guide to AI in life sciences sales: five workflows worth automating, three to leave alone, how to measure it, and a 30-day starting plan.
blog
A decade of SEC Form D filings shows biotech company formation and the median private raise holding steady, while rounds of $50 million and up have fallen.
blog
BIO 2026 will cover AI in R&D, clinical operations, patient engagement, and BD&L forecasting. The gap is meeting-level intelligence for partnering teams.
blog
AI tools are saving sellers time, but most sales organizations are not turning those hours into customer-facing work. Here is why the admin tax persists.
blog
CDMO acquisitions create commercial integration risk long before CRM migration ends. What happens to account knowledge and trust in the first 90 days.
blog
Most AI projects in life sciences never scale past the pilot. Here is why adoption stalls, and how commercial leaders can evaluate AI that changes the work.